Figure 8.

MARV-GP accelerated stability studies results for size-exclusion chromatography and vaccine immunogenicity for the (a, c) 2-week 50°C incubation study and (b, d) 12-week incubation study. (a) Area under the entire chromatogram was calculated and normalized to areas of each unincubated formulation to represent retention of total protein after 50°C incubation. (b) Area under the entire chromatogram, normalized to unincubated areas, was calculated to signify protein retention after 12 weeks of incubation for the MARV-GP LYO pH #2 formulation. Liquid in ammonium acetate at the same conditions and liquid in PBS were also incubated and analyzed for comparison. Error bars are standard deviation from the average of three replicates in both (a) and (b). (c) Mouse immunogenicity of MARV-GP lyophilized formulations at 0 weeks incubation and 2 weeks at 50°C incubation shown as GMTs +/−95% confidence interval. (d) Mouse immunogenicity of MARV-GP LYO pH #2 formulation compared to MARV-GP liquid in PBS. Each dot represents the measured antibody concentration from serum of one individual mouse in both (c) and (d). Sera were diluted 1:8000 for analysis. The dotted line in (c) and (d) represents the LOQ, with values below this limit shown as half the LOQ.